Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Impedimed Limited ( (AU:IPD) ) has issued an announcement.
ImpediMed Limited announced a change in the director’s interest, with Ms. Christine Emmanuel-Donnelly acquiring additional ordinary shares through IDEAHL Pty Ltd. The acquisition was made in lieu of 15% of director fees for the quarter ended 30 September 2025, reflecting a strategic move to align director compensation with company performance. This change in shareholding may impact the company’s governance and stakeholder confidence by demonstrating the director’s commitment to the company’s growth and success.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.13 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
More about Impedimed Limited
ImpediMed Limited operates in the medical technology industry, focusing on the development and sale of bioimpedance spectroscopy devices. These devices are primarily used for the non-invasive assessment of body composition and fluid status, with applications in healthcare sectors such as oncology, cardiology, and renal care.
Average Trading Volume: 1,808,782
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$77.37M
See more data about IPD stock on TipRanks’ Stock Analysis page.